Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Biomed Res Int ; 2014: 975380, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24745029

RESUMO

We evaluated clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C (NBNC) hepatocellular carcinoma (HCC) patients with comparison to hepatitis B or C virus, paying attention to relationship between alcohol consumption and histopathological findings. The medical records on the 201HCC patients who underwent initial hepatectomy between January 2000 and April 2013 were retrospectively reviewed. NBNC patients had higher prevalence of hypertension (47.4%), diabetes mellitus (35.5%), alcohol consumption (>20 g/day) (61.8%), and preserved liver function than hepatitis B or C patients. The 5-year survival rate of NBNC patients (74.1%) was significantly better than hepatitis B (49.1%) or C (65.0%) patients (NBNC versus B, P = 0.031). Among the NBNC patients, there was no relationship between alcohol consumption and clinicopathological findings including nonalcoholic fatty liver disease activity score (NAS). However, the 5-year OS and RFS rates in the alcohol-unrelated NBNC patients tend to be better than in the alcohol-related. By multivariate analysis, independent factors for OS in NBNC patients were Child-Pugh B/C, intrahepatic metastasis (im), and extrahepatic recurrence. NBNC patients, who were highly associated with lifestyle-related disease and preserved liver function, had significantly better prognosis compared to hepatitis B/C patients; however, there was no association between alcohol consumption and histopathological findings.


Assuntos
Carcinoma Hepatocelular , Hepacivirus , Hepatectomia , Vírus da Hepatite B , Hepatite B , Hepatite C , Neoplasias Hepáticas , Idoso , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/cirurgia , Intervalo Livre de Doença , Feminino , Seguimentos , Hepatite B/mortalidade , Hepatite B/patologia , Hepatite B/cirurgia , Hepatite C/mortalidade , Hepatite C/patologia , Hepatite C/cirurgia , Humanos , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade , Recidiva , Estudos Retrospectivos , Taxa de Sobrevida
2.
Congenit Anom (Kyoto) ; 51(3): 102-9, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21848994

RESUMO

The bulbourethral gland (BUG) is a male-specific organ, which secretes part of the semen fluid. As the BUG is located in the deep pelvic floor, its developmental process is still unclear. Bone morphogenetic protein (Bmp) signaling plays pivotal roles in various organs. However, the function of Bmp signaling for BUG development is still unclear. The present study aimed to elucidate the role of Bmp signaling in the development of the BUG. We observed the prominent nuclear accumulation of phosphorylated (p) SMAD1/5/8, the downstream molecules of Bmp signaling, during BUG epithelial development. These results suggest that Bmp signaling contributes to BUG development. Bmp receptor1a (Bmpr1a) is known as the major type 1 signal transducer in some organogeneses. To analyze the Bmp signaling function for BUG development, we examined epithelial cell-specific Bmpr1a gene conditional mutant mice utilizing the tamoxifen-inducible Cre recombinase system. We observed cystic dilation and epithelial hyperplasia of the BUG in the Bmpr1a conditional knockout mice. The mutant cystic BUG specimens also showed inflammatory lesions. These BUG abnormalities resembled some of the BUG malformations observed in human congenital syndromes. The current study suggests that Bmp signaling possesses an essential role in BUG development and homeostasis. This would be the first report showing that the mutation of the Bmpr1a gene in the BUG epithelia phenocopied some abnormalities of human congenital syndromes affecting the BUG duct.


Assuntos
Receptores de Proteínas Morfogenéticas Ósseas Tipo I/genética , Proteínas Morfogenéticas Ósseas/metabolismo , Glândulas Bulbouretrais/anormalidades , Epitélio/crescimento & desenvolvimento , Distúrbios do Assoalho Pélvico/genética , Distúrbios do Assoalho Pélvico/patologia , Animais , Receptores de Proteínas Morfogenéticas Ósseas Tipo I/metabolismo , Glândulas Bulbouretrais/metabolismo , Glândulas Bulbouretrais/patologia , Dilatação Patológica/genética , Dilatação Patológica/patologia , Modelos Animais de Doenças , Epitélio/metabolismo , Epitélio/patologia , Humanos , Hiperplasia/genética , Hiperplasia/patologia , Integrases/metabolismo , Masculino , Camundongos , Camundongos Knockout , Mutação , Transdução de Sinais , Proteína Smad1/metabolismo , Tamoxifeno/farmacologia
3.
Breast Cancer ; 16(3): 179-85, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19466513

RESUMO

Expression profiling of invasive breast carcinomas by DNA microarray techniques has identified five distinct subtypes of tumors (luminal A, luminal B, normal breast-like, HER2 overexpression, and basal-like) that are associated with different clinical outcomes and with different chemotherapy. Basal-like carcinoma is associated with younger patient age, high histological grade, aggressive clinical course, development of distant metastasis, poor prognosis, and relatively high mortality rate. Basal-like carcinomas do not express estrogen receptor, progesterone receptor, or HER2 (triple-negative phenotype). Therefore, patients with basal-like carcinomas are not likely to benefit from endocrine therapies or trastuzumab, but are likely to benefit from systemic chemotherapy. Although genetic, morphological, and immunohistochemical features of basal-like carcinomas have been reported, there is no universal definition for those tumors. Furthermore, there are no specific morphological and immunohistochemical features that can identify those tumors in routine diagnostic materials. In the present paper, we present data of histological and cytological features of basal-like breast carcinoma, and discuss about its morphological spectrum.


Assuntos
Neoplasias da Mama/patologia , Neoplasia de Células Basais/patologia , Biomarcadores Tumorais/análise , Neoplasias da Mama/classificação , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Feminino , Perfilação da Expressão Gênica , Humanos , Imuno-Histoquímica/métodos , Queratinas/análise , Neoplasia de Células Basais/classificação , Neoplasia de Células Basais/genética , Neoplasia de Células Basais/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , Receptor ErbB-2/análise , Receptor ErbB-2/genética , Receptores de Estrogênio/análise , Receptores de Estrogênio/genética
4.
Jpn J Clin Oncol ; 38(2): 122-8, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18272471

RESUMO

OBJECTIVE: Selection criteria for active surveillance (AS) program of localized prostate cancer remain to be standardized. The purpose was to evaluate the validity of selection criteria and investigate the feasibility of this AS program. METHODS: Patients meeting the criteria (i) stage T1cN0M0, (ii) age 50-80, (iii) serum prostate-specific antigen (PSA) 2y', which was defined as the proportion of patients who showed PSADT assessed at 6 months >2 years out of all the patients who chose AS. Point estimate of '%PSADT > 2y' was expected to be >80%. RESULTS: One hundred and eighteen patients opted for AS and 16 chose immediate treatment at enrollment. PSADT for the initial 6 months based on four measurements could be assessed in 106 patients. Intent-to-treat analysis of '%PSADT > 2y' was 71.2% (84/118, 95% CI: 62.1-79.2). Pathological progression rate at 1-year re-biopsy was 33%. Fifty-four (46%) patients remained on AS for maximal observation of 54 months. General health-related QOL in patients undergoing AS was not impaired. CONCLUSIONS: The primary endpoint, '%PSADT > 2y', did not meet the pre-specified decision criteria. Further prospective study with revised program and endpoint is needed.


Assuntos
Seleção de Pacientes , Vigilância da População/métodos , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/patologia , Neoplasias da Próstata/prevenção & controle , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Nível de Saúde , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Estudos Prospectivos , Neoplasias da Próstata/imunologia , Qualidade de Vida
5.
Int J Oncol ; 31(5): 1069-76, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17912432

RESUMO

Methylthioadenosine phosphorylase (MTAP) is an important enzyme in the salvage pathway of adenosine and methionine synthesis. MTAP is ubiquitously present in all normal cells and tissues, but deficient in a variety of malignant tumors. The enzyme deficiency is caused by either MTAP gene deletion or promoter hypermethylation. We investigated MTAP expression, MTAP gene deletion and promoter abnormality in 40 primary tumor samples from Japanese osteosarcoma patients and determined the frequency of the enzyme deficiency. We also tested whether or not the enzyme deficiency can be exploited for tumor-specific chemotherapy using osteosarcoma cell lines. For MTAP expression, immunohistochemistry (IHC) and Western blotting were used. Real-time quantitative PCR assay was used for the analysis of MTAP gene deletion in fifteen osteosarcoma samples. MTAP promoter abnormality was analyzed by methylation-specific PCR. Then, the relationship between MTAP expression and sensitivity to the inhibitors of de novo AMP synthesis was confirmed in an MTAP-negative and -positive osteosarcoma cell line. The MTAP protein was negative in 11 of 40 samples (27.5%) by IHC and in 4 of 6 osteosarcoma cell lines (66.7%) by Western blot analysis. Among 40 samples, 15 were subjected to quantitative real-time PCR and promoter methylation analysis. Of 6 samples that were negative by IHC, the MTAP gene was deleted in 3 and the MTAP promoter was methylated in 2. These results indicated that MTAP deficiency was caused by MTAP gene deletion or promoter methylation in all MTAP-negative samples except one that was negative with IHC although no deletion or promoter methylation was detected. In in vitro experiments using transfectoma along with the MTAP-negative parental cell line, the MTAP-negative parental cell line was more chemosensitive to the inhibitors of de novo AMP synthesis than MTAP-positive transfectoma. MTAP deficiency frequently found in osteosarcoma can be exploited for selective chemotherapy in MTAP-negative osteosarcoma patients with the inhibitors of de novo purine synthesis.


Assuntos
Neoplasias Ósseas/enzimologia , Osteossarcoma/enzimologia , Purina-Núcleosídeo Fosforilase/deficiência , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias Ósseas/tratamento farmacológico , Linhagem Celular Tumoral , Criança , Metilação de DNA , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Osteossarcoma/tratamento farmacológico , Regiões Promotoras Genéticas , Purina-Núcleosídeo Fosforilase/análise , Purina-Núcleosídeo Fosforilase/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa
6.
World J Gastroenterol ; 12(39): 6325-30, 2006 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-17072956

RESUMO

AIM: To examine the influence of lipoprotein lipase (LPL) gene polymorphism in ulcerative colitis (UC) patients. METHODS: Peripheral blood was obtained from 131 patients with UC and 106 healthy controls for DNA extraction. We determined LPL gene polymorphisms affecting the enzyme at Ser447stop, as well as Hind III and Pvu II polymorphisms using PCR techniques. PCR products were characterized by PCR-RFLP and direct sequencing. Polymorphisms were examined for association with clinical features in UC patients. Genotype frequencies for LPL polymorphisms were also compared between UC patients and controls. RESULTS: In patients with onset at age 20 years or younger, C/G and G/G genotypes for Ser447stop polymorphism were more prevalent than C/C genotype (OR = 3.13, 95% CI = 0.95-10.33). Patients with H(+/-) or H(-/-) genotype for Hind III polymorphism also were more numerous than those with H(+/+) genotype (OR = 2.51, 95% CI = 0.85-7.45). In the group with H(+/+) genotype for Hind III polymorphism, more patients had serum triglyceride concentrations over 150 mg/dL than patients with H(+/-) or H(-/-) genotype (P < 0.01, OR = 6.46, 95% CI = 1.39-30.12). Hypertriglycemia was also more prevalent in patients with P(+/+) genotypes for Pvu II polymorphism (P < 0.05, OR = 3.0, 95% CI = 1.06-8.50). Genotype frequency for LPL polymorphism did not differ significantly between UC patients and controls. CONCLUSION: Ser447stop and Hind III LPL polymorphisms may influence age of onset of UC, while Hind III and Pvu II polymorphisms influence serum triglyceride in UC patients.


Assuntos
Colite Ulcerativa/enzimologia , Colite Ulcerativa/genética , Lipase Lipoproteica/genética , Polimorfismo Genético , Adulto , Estudos de Casos e Controles , Colite Ulcerativa/sangue , Colite Ulcerativa/etiologia , Feminino , Regulação Enzimológica da Expressão Gênica/genética , Genótipo , Humanos , Incidência , Lipase Lipoproteica/metabolismo , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Triglicerídeos/sangue
7.
Urology ; 66(2): 332-7, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16098362

RESUMO

OBJECTIVES: To evaluate multiple known prognostic markers in localized prostate cancer using tissue microarrays in Japanese patients. Molecular studies have suggested that ethnicity influences prostate tumor biology. METHODS: Specimens were studied from 52 patients who underwent radical surgery at our institution between 1997 and 2001 without neoadjuvant hormonal therapy and with three or more available and complete cancer spots. Ki67, p53, and androgen receptor antigen expression were examined. Immunohistochemical scores were compared with outcomes of chemical relapse as monitored using prostate-specific antigen. RESULTS: Pathologic tumor classification (P = 0.047), World Health Organization score (P = 0.026), World Health Organization histologic grade (P = 0.026), and surgical margin status (P = 0.018) were significant conventional clinicopathologic variables for predicting biochemical failure. The tissue microarray Gleason sum (P = 0.038), tissue microarray primary Gleason grade (P = 0.013), Ki67 labeling index (P < 0.0001), p53 (P = 0.0097), and androgen receptor (P = 0.0113) antigen expression also were significant. Moreover, surgical margin status and Ki67 labeling index were independently associated with treatment failure. CONCLUSIONS: Especially together, the Ki67 labeling index and p53 and androgen receptor expression in localized prostate cancer often predicted postoperative progression in Japanese patients.


Assuntos
Antígeno Ki-67/biossíntese , Prostatectomia , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/cirurgia , Receptores Androgênicos/biossíntese , Proteína Supressora de Tumor p53/biossíntese , Idoso , Humanos , Japão , Antígeno Ki-67/análise , Masculino , Pessoa de Meia-Idade , Prognóstico , Neoplasias da Próstata/química , Neoplasias da Próstata/patologia , Receptores Androgênicos/análise , Falha de Tratamento , Proteína Supressora de Tumor p53/análise
8.
Pediatr Blood Cancer ; 45(1): 64-7, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15770642

RESUMO

A 24-year-old woman presented with anaplastic transformation from papillary thyroid carcinoma with increased serum CA19-9. The patient had been diagnosed as having papillary thyroid carcinoma with lung metastasis at 11 years of age. She received a total thyroidectomy with cervical lymph node dissection followed by iodine-131 ((131)I) therapy over 12 years, but died due to sudden onset of rapid dissemination. Elevated serum CA19-9 was detected in the terminal stage, and anaplastic transformation was confirmed by post-mortem examination. Although there are few clinical reports suggesting a prognostic indicator for anaplastic thyroid carcinoma, CA19-9 may be a useful serum marker for this tumor.


Assuntos
Antígeno CA-19-9/sangue , Carcinoma Papilar/patologia , Carcinoma/sangue , Neoplasias da Glândula Tireoide/sangue , Neoplasias da Glândula Tireoide/patologia , Adulto , Anaplasia/sangue , Carcinoma/secundário , Transformação Celular Neoplásica , Evolução Fatal , Feminino , Humanos , Neoplasias da Glândula Tireoide/secundário
9.
Oncol Rep ; 10(6): 1961-5, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14534726

RESUMO

We examined the effects of inactivation of the RB gene on chemosensitivity of human osteosarcoma cell lines, using the MTT assay and calculating the inhibition index. Although the human osteosarcoma cell lines HOS and MG63 have a wild-type RB gene, SaOS-2 and OSrb (established from retinoblastoma patient) have no active RB gene. We used these 4 cell lines in growth inhibition assays for doxorubicin, cisplatin and methotrexate, and assessed the chemosensitivity. In the growth inhibition assay for methotrexate, cell lines lacking an active RB gene were more resistant than cell lines with an active RB gene.


Assuntos
Resistencia a Medicamentos Antineoplásicos , Regulação Neoplásica da Expressão Gênica , Osteossarcoma/metabolismo , Proteína do Retinoblastoma/biossíntese , Antibióticos Antineoplásicos/farmacologia , Antineoplásicos/farmacologia , Northern Blotting , Western Blotting , Divisão Celular , Linhagem Celular Tumoral , Cisplatino/farmacologia , Corantes/farmacologia , Relação Dose-Resposta a Droga , Doxorrubicina/farmacologia , Éxons , Genes p53/genética , Humanos , Metotrexato/farmacologia , Polimorfismo Conformacional de Fita Simples , Proteína do Retinoblastoma/genética , Sais de Tetrazólio/farmacologia , Tiazóis/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...